uCLU/Cr

Biomarker

1 paper mentions it1 finding

See all 1

Interventions

1

Atrasentan

downin humans1

1 study
  1. Atrasentan decreases uCLU/Cr in humans (-46.3% (95% CI -57.8 to -37.1)).

    “Six weeks of treatment with atrasentan resulted in a significant reduction in urinary clusterin excretion and an increase in sET-1 levels.”

    Human trialn = 308

    Urine proteins may aid drug monitoring in kidney disease

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Atrasentan

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months
Nephrology, Dialysis, Transplantation

Urine proteins may aid drug monitoring in kidney disease

A urine protein measure linked to kidney injury fell 46.3% from baseline after six weeks of atrasentan in people with chronic kidney disease.A urine protein measure linked to kidney injury fell 46.3% from baseline after six weeks of atrasentan in people with chronic kidney disease.

Randomized trial · 2,303 peopleBiomarkers